The European Society of Cardiology/ European Society for Atherosclerosis released in 2017 a practical guideline for the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia [25]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.